Taiqian Gong

Taiqian Gong


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JZJiale Zhang
Jiale Zhang
YDYanxin Dong
Yanxin Dong
SDShouyin Di
Shouyin Di
SXShun Xie
Shun Xie
BFBoshi Fan
Boshi Fan
TGTaiqian Gong
Taiqian Gong
Esophageal squamous carcinoma (ESCC) is a prevalent and highly lethal malignant tumor, with a five-year survival rate of approximately 20 %. Tumor-associated macrophages (TAMs) are the most prominent immune cells in the tumor microenvironment (TME), comprising over 50 % of the tumor volume. TAMs can be polarized into two distinct phenotypes, M1-type and M2-type, through interactions with cancer cells. M2-type TAMs are more abundant than M1-type TAMs in the TME, contributing to tumor progression, such as tumor cell survival and the construction of an immunosuppressive environment. This review focuses on the role of TAMs in ESCC, including their polarization, impact on tumor proliferation, angiogenesis, invasion, migration, therapy resistance, and immunosuppression. In addition, we discuss the potential of targeting TAMs for clinical therapy in ESCC. A thorough comprehension of the molecular biology about TAMs is essential for the development of innovative therapeutic strategies to treat ESCC.

24 October 2012 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
WGWei Guo
Wei Guo
YZYing-Bo Zou
Ying-Bo Zou
ZMZheng Ma
Zheng Ma
HNHui-Jun Niu
Hui-Jun Niu
YJYao-Guang Jiang
Yao-Guang Jiang
RWRu-Wen Wang
Ru-Wen Wang

24 October 2014 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
XZXiushan Zheng
Xiushan Zheng
JDJiaqiang Dong
Jiaqiang Dong
TGTaiqian Gong
Taiqian Gong
ZZZhiyong Zhang
Zhiyong Zhang
YWYing Wang
Ying Wang
MDMingfan Dai
Mingfan Dai

1 April 2018 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
HLHui Li
Hui Li
WFWentao Fang
Wentao Fang
ZYZhentao Yu
Zhentao Yu
YMYousheng Mao
Yousheng Mao
LCLongqi Chen
Longqi Chen
TOThe Society of Esophageal Tumor, Chinese Anti-Cancer Association, on behalf of
The Society of Esophageal Tumor, Chinese Anti-Cancer Association, on behalf of
Chinese expert consensus on mediastinal lymph node dissection in esophagectomy for esophageal cancer (2017 edition)

28 February 2020 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
WSWeian Song
Weian Song
SDShouyin Di
Shouyin Di
JLJunqiang Liu
Junqiang Liu
BFBoshi Fan
Boshi Fan
JZJiahua Zhao
Jiahua Zhao
TGTaiqian Gong
Taiqian Gong
Background: Tumor recurrence or residual tumor after targeted therapy is common in patients with advanced non‐small cell lung cancer (NSCLC). There is a lack of high‐level evidence on which type of treatment should be employed for these patients and the role of salvage surgery has not been well reported in the literature.Methods: A retrospective analysis of patients who underwent salvage surgery in our center between January 2016 and June 2019 for advanced NSCLC after targeted therapy was performed.Results: A total number of nine patients were identified, including five males and four females, with a median age of 56 years (range, 40–65 years), all diagnosed with lung adenocarcinoma stage IIIa–IVb. All patients had received targeted therapy according to individual positive mutation of driver gene(s). Salvage surgery was performed for tumor recurrence or residual tumor after a duration of 2–46 months of targeted therapy. A negative surgical margin was achieved in all cases. Postoperative complication rate was 11.1% (1/9). All patients were alive at the time of this analysis and two patients had disease progression. After a median follow‐up of 17 months (range: 5–44 months), the median event‐free survival and postoperative survival was 14 months (range: 2–44 months) and 17 months (range: 5–44 months) respectively.Conclusions: Salvage surgery may be a feasible and promising therapeutic option for tumor recurrence or residual tumor in advanced NSCLC in selective patients after targeted therapy.Key points: Salvage surgery is feasible in selected patients with advanced NSCLC and provides promising survival outcomes after targeted therapy failure. Salvage surgery provides precise molecular and pathological information which is most important for subsequent therapy.

1 June 2012 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
PDF file
TGTaiqian Gong
Taiqian Gong
ZXZengfu Xue
Zengfu Xue
STShanhong Tang
Shanhong Tang
XZXiushan Zheng
Xiushan Zheng
GXGuanghui Xu
Guanghui Xu
MDMingfan Dai
Mingfan Dai
Twist-1 protein (also called Twist) has been suggested to be involved in tumor epithelial-mesenchymal transition (EMT) related progression, however, the mechanism by which twist promotes lymph node metastasis is not fully understood. In the present study, we found that nuclear twist expression is clearly correlated with lymph node (LN) metastasis as determined by immunohistochemistry (IHC). A highly invasive EC109 cell subline, EC109-P, was established by repeated in vitro transwell isolations for the cell model. Immunofluorescence (IF) assay demonstrated that nuclear twist expression was markedly higher in the highly invasive EC109-P cell line when compared with EC109 and EC9706 cells. Based on our cell model, the function and mechanism by which twist regulates LN metastasis in ESCC was investigated. The results showed that the overexpression of Twist could significantly increase the invasion and VEGF-C expression of EC9706 cells, whereas the knockdown of twist expression results in the opposite effects. This finding was further strengthened by the results of the analysis of co-expression of twist and VEGF-C by IHC in ESCC clinical samples. In summary, our study indicates that nuclear twist plays an important role in ESCC lymphatic metastasis by increasing the expression of VEGF-C. The combination of twist and VEGF-C detection could be a reliable prediction of LN metastasis in ESCC.